safety update anthony ormerod. why is safety important? clinical trial / european directive mhra /...
TRANSCRIPT
![Page 1: Safety update Anthony Ormerod. Why is safety important? Clinical trial / European directive MHRA / governance Severe disease Patients have large burden](https://reader036.vdocuments.site/reader036/viewer/2022082709/56649f515503460f94c74618/html5/thumbnails/1.jpg)
Safety update
Anthony Ormerod
![Page 2: Safety update Anthony Ormerod. Why is safety important? Clinical trial / European directive MHRA / governance Severe disease Patients have large burden](https://reader036.vdocuments.site/reader036/viewer/2022082709/56649f515503460f94c74618/html5/thumbnails/2.jpg)
Why is safety important?
• Clinical trial / European directive• MHRA / governance• Severe disease• Patients have large burden of co-morbidities• Patients with PG are more likely to die• Drugs used in therapy are toxic
![Page 3: Safety update Anthony Ormerod. Why is safety important? Clinical trial / European directive MHRA / governance Severe disease Patients have large burden](https://reader036.vdocuments.site/reader036/viewer/2022082709/56649f515503460f94c74618/html5/thumbnails/3.jpg)
Pragmatic trial
• Driven by clinical judgement• Would you normally be comfortable
![Page 4: Safety update Anthony Ormerod. Why is safety important? Clinical trial / European directive MHRA / governance Severe disease Patients have large burden](https://reader036.vdocuments.site/reader036/viewer/2022082709/56649f515503460f94c74618/html5/thumbnails/4.jpg)
Weight
• Ciclosporin 4mg/kg• Prednisolone 0.75mg/kg
• Since Sept 2011• Ceiling of 100kg• Maximum ciclosporin 400mg/d• Maximum prednisolone 75mg/ day
![Page 5: Safety update Anthony Ormerod. Why is safety important? Clinical trial / European directive MHRA / governance Severe disease Patients have large burden](https://reader036.vdocuments.site/reader036/viewer/2022082709/56649f515503460f94c74618/html5/thumbnails/5.jpg)
Neoral contra-indications
• Impaired renal function• Uncontrolled hypertension• Infection• Malignancy
![Page 6: Safety update Anthony Ormerod. Why is safety important? Clinical trial / European directive MHRA / governance Severe disease Patients have large burden](https://reader036.vdocuments.site/reader036/viewer/2022082709/56649f515503460f94c74618/html5/thumbnails/6.jpg)
SPC Neoral what’s new?
• Creatinine 2 weekly for first 3 months• Lipids before and at 1 month• Hepato-toxicity in transplants– Cholestasis – Jaundice– Hepatitis– Liver failure
![Page 7: Safety update Anthony Ormerod. Why is safety important? Clinical trial / European directive MHRA / governance Severe disease Patients have large burden](https://reader036.vdocuments.site/reader036/viewer/2022082709/56649f515503460f94c74618/html5/thumbnails/7.jpg)
Neoral Interactions• P glycoprotein PgP inhibited• Aliskiren levels increased• Myositis rhabdomyolysis with statins– Lovastatin– Simvastatin– Atorvastatin– Pravastatin– Fluvastatin– Reduce dose
• Digoxin (toxicity)• Colchicine (peripheral neuropathy, myositis)
![Page 8: Safety update Anthony Ormerod. Why is safety important? Clinical trial / European directive MHRA / governance Severe disease Patients have large burden](https://reader036.vdocuments.site/reader036/viewer/2022082709/56649f515503460f94c74618/html5/thumbnails/8.jpg)
Alisikiren??• The Medicines and Healthcare products Regulatory Agency (MHRA)
has recommended that doctors review the treatment of all patients taking aliskiren (Rasilez) for raised blood pressure. This advice follows the results of a study of diabetic patients taking both aliskiren and an angiotensin converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB). With this combination the study showed patients were unlikely to benefit from aliskiren and also reported higher than expected incidence of non-fatal stroke, kidney complications, high blood potassium levels and low blood pressure. Doctors have been advised to review the treatment of all patients currently taking aliskiren. In particular, if patients are diabetic and also taking an ACE inhibitor or ARB, then their treatment with aliskiren should be stopped and alternative treatments considered.
![Page 9: Safety update Anthony Ormerod. Why is safety important? Clinical trial / European directive MHRA / governance Severe disease Patients have large burden](https://reader036.vdocuments.site/reader036/viewer/2022082709/56649f515503460f94c74618/html5/thumbnails/9.jpg)
Prednisolone• Abdominal distension• Acute pancreatitis• Dypepsia• Nausea• Increased appetite• Oesophageal candidiasis• Oesophageal ulceration• Peptic ulceration – perforation and haemorrhage
• Perforation of small bowel– Especially patients with inflammatory bowel disease
![Page 10: Safety update Anthony Ormerod. Why is safety important? Clinical trial / European directive MHRA / governance Severe disease Patients have large burden](https://reader036.vdocuments.site/reader036/viewer/2022082709/56649f515503460f94c74618/html5/thumbnails/10.jpg)
What to do
• Keep good records• Ask about adverse events• Is it related to intervention?• Is it severe?• Is it expected?• If related report Adverse Reactions• If severe (SAE) report in 24 hours of becoming
aware